ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,115.38
-0.14%
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs Yen
143.825
0.01%
Brent Oil
74.135
0.00%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. XORTX Therapeutics Inc (XRTX)

  7. XORTX Therapeutics Inc (XRTX) ニュース

XRTX

XORTX Therapeutics (XRTX)

XORTX Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:XRTX
日付受信時刻ニュースソース見出しコード企業名
2024/09/1405 : 20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/09/1405 : 10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/09/1320 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/09/1320 : 00GlobeNewswire Inc.XORTX Announces Results of Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
2024/09/1306 : 30GlobeNewswire Inc.XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&ANASDAQ:XRTXXORTX Therapeutics Inc
2024/09/0706 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/09/0706 : 30GlobeNewswire Inc.XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
2024/09/0401 : 30GlobeNewswire Inc.Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2920 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2920 : 00GlobeNewswire Inc.XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismNASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2321 : 13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2320 : 00GlobeNewswire Inc.XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2220 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2104 : 11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
2024/08/2020 : 00GlobeNewswire Inc.XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024NASDAQ:XRTXXORTX Therapeutics Inc
2024/07/1305 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/07/1305 : 05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 17Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1405 : 08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
2024/06/1220 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XRTX

最近閲覧した銘柄

FX
USDJPY
US Dollar vs Yen
SPI
SP500
S&P 500
AMEX
XLE
Energy Select Sector SPDR
NYSE
CVX
Chevron
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
SPY
SPDR S&P 500
COIN
DOGEUSD
Dogecoin
NYSE
AXP
American Express
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
USOTC
ADDYY
Adidas (QX)
COIN
XRPUSD
Ripple
NYSE
JPM
JP Morgan Chase
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有